文献速递糖尿病

美国新诊断1型糖尿病患儿持续葡萄糖监测联合远程患者监测的成本效果

Cost-Effectiveness of Continuous Glucose Monitoring With Remote Patient Monitoring in Pediatric Patients With Newly Diagnosed Type 1 Diabetes in the U.S.
PubMed 文献 · Diabetes Care · 2026-01-01

本研究采用马尔可夫模型模拟5岁新诊断1型糖尿病患儿20年、50年及终身病程,比较自我血糖监测(SMBG)、持续葡萄糖监测(CGM)及CGM联合远程患者监测(RPM)的成本效果。结果显示,与SMBG相比,CGM联合RPM增加0.37个质量调整生命年(QALY),成本增加10,300美元;其增量成本效果比为27,400美元/QALY,低于CGM单独使用的103,700美元/QALY。结论认为CGM联合RPM可能具有成本效果。

要点

  • CGM联合RPM较SMBG增加0.37 QALY,成本增加10,300美元。
  • CGM联合RPM的ICER为27,400美元/QALY,优于CGM单独使用。
  • CGM联合RPM在达到4T研究至少30%临床效力时仍具成本效果。

核心结论

  • CGM联合RPM较SMBG和CGM单独使用带来更优健康结局,对新诊断1型糖尿病患儿可能具有成本效果。
  • 尽管干预成本较高,CGM联合RPM可降低并发症成本并产生净医疗费用节省。

研究设计与样本

  • 采用马尔可夫模型模拟5岁新诊断1型糖尿病患者的疾病进展。
  • 评估时间跨度包括20年、50年和终身。
  • 比较三种干预措施:SMBG、CGM、CGM联合RPM。
  • 疗效估计来自儿童CGM研究的荟萃分析和4T研究1的结果。
  • 评估质量调整生命年(QALY)和医疗费用(2022年美元),按3%年贴现率贴现,并进行广泛敏感性分析。

主要发现

  • 与SMBG相比,CGM在20年内增加0.09 QALY,成本增加8,900美元。
  • 与SMBG相比,CGM联合RPM增加0.37 QALY,成本增加10,300美元。
  • CGM联合RPM的增量成本效果比为27,400美元/QALY,CGM单独使用为103,700美元/QALY。
  • 结果在敏感性分析和不同时间跨度中稳健。
  • CGM联合RPM在达到4T研究至少30%临床效力时仍具成本效果。

临床怎么用

  • 对于新诊断1型糖尿病患儿,可考虑使用CGM联合RPM以改善健康结局并可能节省医疗费用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The use of continuous glucose monitoring (CGM) with remote patient monitoring (RPM) continues to grow. We evaluated the cost-effectiveness of CGM with RPM compared with self-monitoring of blood glucose (SMBG) and CGM alone. RESEARCH DESIGN AND METHODS: We simulated type 1 diabetes progression with a Markov model in 5-year-old patients over a 20-year, 50-year, and lifetime horizon. We tracked diabetic ketoacidosis (DKA), severe hypoglycemia (SH), and seven chronic complications: retinopathy, neuropathy, nephropathy, cardiovascular disease, end-stage renal disease, lower-extremity amputation, and blindness. We compared three interventions: SMBG, CGM, and CGM with RPM. Efficacy estimates were derived from meta-analyses of pediatric CGM studies and the results of the Teamwork, Targets, Technology, and Tight Glycemia Study (4T Study 1). We evaluated quality-adjusted life years (QALYs) and health care costs (2022 U.S. dollars) discounted at 3% annually. We performed extensive sensitivity analyses. RESULTS: Compared with SMBG, CGM increased QALYs by 0.09 and costs by $8,900 over 20 years; CGM with RPM increased QALYs by 0.37, and costs by $10,300. CGM with RPM yielded more QALYs at a lower incremental cost-effectiveness ratio compared with CGM ($27,400/QALY vs. $103,700/QALY, respectively). Results were robust across sensitivity analyses and time horizons. CGM with RPM remained cost-effective when achieving at least 30% of 4T's clinical efficacy. CONCLUSIONS: CGM with RPM delivers superior health outcomes compared with SMBG and CGM and is likely cost-effective for patients with newly diagnosed type 1 diabetes. Despite higher intervention costs, CGM with RPM can reduce complications costs and generate net health care savings.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Dupenloup P, Chen Y, Prahalad P, et al. Cost-Effectiveness of Continuous Glucose Monitoring With Remote Patient Monitoring in Pediatric Patients With Newly Diagnosed Type 1 Diabetes in the U.S. Diabetes Care. 2026. PMID: 41879358. doi:10.2337/dc25-2825

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。